期刊
CANCER
卷 124, 期 6, 页码 1111-1121出版社
WILEY
DOI: 10.1002/cncr.31200
关键词
adrenal insufficiency; autoimmune diabetes; immune checkpoint inhibitors; immune-related adverse events; hyperthyroidism; hypophysitis; hypothyroidism; thyroiditis
类别
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, because ICIs block coinhibitory molecules on T cells and other immune cells, unleashing them to mediate tumor cell killing, they also can disrupt the maintenance of immunological tolerance to self-antigens. Compared with chemotherapy, ICIs have a different toxicity profile, especially the occurrence of autoimmune-like manifestations against multiple organ systems, including endocrine glands, commonly referred to as immune-related adverse events. The aim of this review was to provide practical recommendations regarding the proper assessment and clinical management related to the new onset of endocrinopathies after the use of ICIs in patients with cancer. (c) 2018 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据